Ad is loading...
PRAX
Price
$73.06
Change
-$0.62 (-0.84%)
Updated
Nov 21 closing price
110 days until earnings call
ZYME
Price
$13.68
Change
-$0.87 (-5.98%)
Updated
Nov 21 closing price
Ad is loading...

PRAX vs ZYME

Header iconPRAX vs ZYME Comparison
Open Charts PRAX vs ZYMEBanner chart's image
Praxis Precision Medicines
Price$73.06
Change-$0.62 (-0.84%)
Volume$307.26K
CapitalizationN/A
Zymeworks
Price$13.68
Change-$0.87 (-5.98%)
Volume$714.02K
CapitalizationN/A
PRAX vs ZYME Comparison Chart
Loading...
PRAX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
PRAX vs. ZYME commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRAX is a Sell and ZYME is a Buy.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (PRAX: $73.06 vs. ZYME: $13.68)
Brand notoriety: PRAX and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRAX: 100% vs. ZYME: 127%
Market capitalization -- PRAX: $1.37B vs. ZYME: $1B
PRAX [@Biotechnology] is valued at $1.37B. ZYME’s [@Biotechnology] market capitalization is $1B. The market cap for tickers in the [@Biotechnology] industry ranges from $463.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRAX’s FA Score shows that 0 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).

  • PRAX’s FA Score: 0 green, 5 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, ZYME is a better buy in the long-term than PRAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRAX’s TA Score shows that 2 TA indicator(s) are bullish while ZYME’s TA Score has 3 bullish TA indicator(s).

  • PRAX’s TA Score: 2 bullish, 6 bearish.
  • ZYME’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ZYME is a better buy in the short-term than PRAX.

Price Growth

PRAX (@Biotechnology) experienced а -4.97% price change this week, while ZYME (@Biotechnology) price change was -15.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.74%. For the same industry, the average monthly price growth was -7.78%, and the average quarterly price growth was +1.53%.

Reported Earning Dates

PRAX is expected to report earnings on Mar 12, 2025.

ZYME is expected to report earnings on May 08, 2023.

Industries' Descriptions

@Biotechnology (-3.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRAX($1.37B) has a higher market cap than ZYME($1B). PRAX YTD gains are higher at: 227.917 vs. ZYME (31.665). ZYME has higher annual earnings (EBITDA): -110.13M vs. PRAX (-163.59M). PRAX has more cash in the bank: 357M vs. ZYME (297M). PRAX has less debt than ZYME: PRAX (1.66M) vs ZYME (20.2M). ZYME has higher revenues than PRAX: ZYME (62.2M) vs PRAX (1.61M).
PRAXZYMEPRAX / ZYME
Capitalization1.37B1B137%
EBITDA-163.59M-110.13M149%
Gain YTD227.91731.665720%
P/E RatioN/AN/A-
Revenue1.61M62.2M3%
Total Cash357M297M120%
Total Debt1.66M20.2M8%
FUNDAMENTALS RATINGS
ZYME: Fundamental Ratings
ZYME
OUTLOOK RATING
1..100
68
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
94
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
75
SEASONALITY SCORE
1..100
18

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
PRAXZYME
RSI
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
74%
MACD
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 11 days ago
83%
Declines
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 1 day ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
77%
Aroon
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Ad is loading...
PRAX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AKREX69.771.01
+1.47%
Akre Focus Retail
DCREX13.380.10
+0.75%
Dunham Real Estate Stock C
ESECX33.140.23
+0.70%
Eaton Vance Atlanta Capital Sel Eq C
PCBSX14.620.10
+0.69%
BlackRock Tactical Opportunities Service
CFGRX55.630.10
+0.18%
Commerce Growth

PRAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with VERU. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then VERU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRAX
1D Price
Change %
PRAX100%
-0.84%
VERU - PRAX
35%
Loosely correlated
+0.42%
INZY - PRAX
34%
Loosely correlated
-3.58%
ZYME - PRAX
33%
Loosely correlated
-5.98%
CLRB - PRAX
33%
Loosely correlated
+1.28%
CYTK - PRAX
32%
Poorly correlated
-4.39%
More

ZYME and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with BEAM. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZYME
1D Price
Change %
ZYME100%
-5.98%
BEAM - ZYME
48%
Loosely correlated
-3.72%
VERV - ZYME
43%
Loosely correlated
+1.10%
ALEC - ZYME
43%
Loosely correlated
+3.44%
NKTX - ZYME
42%
Loosely correlated
-2.40%
RXRX - ZYME
42%
Loosely correlated
-4.80%
More